Breast Cancer | Specialty

Distinct Strategies Needed for Treating Lobular Breast Cancer

April 29th 2015

Although patients with invasive lobular carcinoma are typically treated with the same therapeutic strategies as those with infiltrating ductal malignancies, ILC is emerging as a molecularly complex and distinct tumor type that suggests different approaches may be effective.

Dense Breasts Found in More Black Than White Women, Risk Could Help Target Cancer

April 27th 2015

Black/African-American women had a significantly higher absolute area breast density of 40.1 cm2 compared with 33.1 cm2 in white women.

Broad BRCA Screening is Becoming a Thorny Public Health Issue

April 23rd 2015

Population-based cancer screening using genetic sequencing technology is an idea worthy of careful consideration, but there are many challenges to implementing such a program.

Phase III Trial of Breast Cancer Vaccine Nelipepimut-S Now Fully Enrolled, Mittendorf Discusses Next Steps

April 22nd 2015

OncLive spoke with Elizabeth A. Mittendorf, MD, PhD, to learn more about the PRESENT trial and the potential impact of nelipepimut-S in breast cancer.

Olaparib Plus BKM120 Combo Gains Traction in Breast and Ovarian Cancers

April 21st 2015

A two-pronged strategy combining the PARP inhibitor olaparib and the PI3K inhibitor BKM120 proved to be a safe and clinically beneficial regimen for women with triple-negative breast cancer and for patients with high-grade serous ovarian cancer.

Dr. Mittendorf on Nelipepimut-S in Breast Cancer

April 21st 2015

Elizabeth A. Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses nelipepimut-S (NeuVax) and a proposed trial for patients with ductal carcinoma in situ (DCIS).

Anti-PD-L1 Agent MPDL3280A Shows Durable Responses in TNBC

April 20th 2015

The PD-L1 inhibitor MPDL3280A demonstrated a 19% objective response rate (ORR) with 75% of responses ongoing in pretreated patients with metastatic triple-negative breast cancer.

MM-302 Shows Clinical Activity, Tolerability in Heavily-Pretreated HER2+ Breast Cancer

April 20th 2015

MM-302, a novel antibody-drug conjugate that specifically targets cancer cells overexpressing the HER2 receptor, showed signs of clinical activity in heavily pretreated patients with metastatic, HER2-positive breast cancer.

Dr. Roy Weiner on the Importance of Diversity in Cancer Research

April 17th 2015

Roy Weiner, MD, Associate Dean for Clinical Research and Training Associate Director of Clinical Research for Tulane Cancer Center discusses the importance of racial and ethnic diversity in cancer research.

Palbociclib Delays Breast Cancer Progression in Phase III Trial

April 15th 2015

The PALOMA-3 trial examining a palbociclib regimen in HR+/HER2- breast cancer was halted after an independent panel determined it met the primary endpoint of improving progression-free survival.

BET Bromodomain Inhibitors May Prevent Treatment Resistance in HER2-Positive Breast Cancer

April 14th 2015

Gary L. Johnson, PhD, discusses how BET bromodomain inhibitors could offer a potential solution to lapatinib resistance in patients with HER2-postive breast cancer.

Dr. Irwin on Exercise and Weight Loss After Breast Cancer Diagnosis

April 6th 2015

Melinda L. Irwin, PhD, MPH, associate professor, Yale School of Public Health, co-program leader, Cancer Prevention and Control Research Program, Yale Cancer Center, discusses the results of a study she conducted examining the effects of exercise and weight loss in patients with breast cancer.

Future AACR President Discusses Her Leadership Goals and Research Experience

April 3rd 2015

In an interview with OncLive, Nancy E. Davidson discusses her leadership plans for the AACR, as well as precision medicine in oncology®, challenges with research funding, and the role of epigenetics in breast cancer.

Dr. Hudis on Approaching the Topic of Obesity in Cancer

April 2nd 2015

Clifford A. Hudis, MD, chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the challenges with approaching the topic of obesity in patients with cancer.

mTOR Biology and the Growing Role for mTOR Inhibitors in the Management of Breast Cancer

March 27th 2015

The role of mTOR inhibition in breast cancer is evolving, and ongoing studies are evaluating biomarkers that will identify the patients who will benefit.

Baylor Sammons Cancer Center Provides Patient-Centered Care

March 26th 2015

BEACON Trial Results, Diet, Obesity, and More

March 26th 2015

Hope Rises for Immunotherapy in Breast Cancer

March 25th 2015

Elizabeth A. Mittendorf, MD, PhD, differentiates the main types of immunotherapy, highlights some of the most interesting results in breast cancer trials, and discusses why different types of immunotherapy might be appropriate for different types of breast tumors at various stages of development.

Dr. Sledge on Using PCR To Determine Therapy Benefit for Breast Cancer

March 24th 2015

George W. Sledge, Jr., MD, professor of medicine, Stanford University School of Medicine discusses the benefits of using pathological complete response rate (PCR) to understand therapy benefit in breast cancer.

Pegram Discusses Optimal Pertuzumab Use in HER2-Positive Breast Cancer

March 24th 2015

In an interview with OncLive, Mark D. Pegram, MD, discusses what available data suggest is the optimal use of pertuzumab for the management of HER2-positive breast cancer.